Adneuris Therapeutics Inc.
South Brunswick Township, NJ Park Therapeutics Inc.
- UEI
- LKW7MCDM3GG5
- CAGE
- 8TKS5
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2031 US-130, Monmouth Junction, NJ 08852, USA
- Website
- parktherapeutics.com
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of cebranopadol, a potent dual mop/NOP agonist, for the treatment of opioid use disorder (OUD) | National Institute on Drug Abuse (NIH) | $16,642,955 |
Quick answers
Is Adneuris Therapeutics Inc. registered in SAM.gov?
Yes. Adneuris Therapeutics Inc.'s SAM.gov registration is active through July 1, 2027.
What is Adneuris Therapeutics Inc.'s most recent federal award?
Adneuris Therapeutics Inc.'s most recent federal grant award is Development of cebranopadol, a potent dual mop/NOP agonist, for the treatment of opioid use disorder (OUD) (UG3DA059285), from National Institute on Drug Abuse (NIH), on August 15, 2023.
On GovTribe
See Adneuris Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors